Pharmacogenomics, the study of the impact of heritable traits on pharmacology and toxicology, may serve as an adjunct for certifying opioid fatalities. Oxycodone, frequently prescribed for the relief of moderate to severe pain, is metabolized by cytochrome P450 (CYP) 2D6, encoded by a polymorphic gene with three mutations (*3, *4, and *5) with a combined 95% allelic frequency and about 10% prevalence. Individuals with variant alleles are more susceptible to oxycodone toxicity. By assessing the prevalence of CYP2D6 polymorphisms and covariables, we hypothesized that oxycodone fatality may be partially due to poor drug metabolism caused by CYP2D6 variant alleles. From the Milwaukee County Medical Examiner's Office (MCMEO), a retrospective analysis of 15 oxycodone cases was followed by genotyping blood samples for the variant alleles by conventional and real-time PCRs. Institutional Review Board approval was obtained. Oxycodone, extracted from blood and/or urine, was quantitated by GC-MS. The results show two homozygous for 2D6"4 and four heterozygous for 2D6"4. The MCMEO was not significantly different from those in the control group (n = 26) (p > 0.05, Fisher's Exact Test). However, genotyping CYP2D6 provided a more definitive interpretation of the oxycodone toxicity in four cases. Therefore, pharmacogenomics may serve as an adjunct in the determination of the cause and manner of death in forensic toxicology and a pharmacogenomic algorithm for genotyping has been proposed.
Introduction
In the postgenomic era, molecular techniques are now becoming increasingly important in the diagnostic and clinical laboratory. In fact, pharmacogenetics may be one of the most immediate clinical applications of the Human Genome Project (1) . Pharmacogenomics is the study of the linkage between an individual's genotype and that individual's ability to metabolize a foreign compound (2) . Most xenobiotics, including therapeutic drugs, are metabolized by cytochromes P450 to some extent. The metabolism of these drugs results in the detoxification and elimination of the drug or the activation of the prodrug to its biologically active form. Cytochromes P450 show a wide interindividual variation in their protein expression and/or catalytic activity, resulting in unique drug metabolism. This variation can be due to transient causes such as enzyme inhibition or induction or to permanent causes such as genetic mutations or deletions.
Among the P450 subfamilies, CYP2D6 plays a critical role in determining the response to several drug groups/families (3) . In fact, CYP2D6, debrisoquine/sparteine hydroxylase, is involved in the metabolism of ~ 25% of all medications (4), including oxycodone. The activity of CYP2D6 ranges from complete deficiency to ultrafast metabolism mediated by at least 16 different known alleles. These differences in drug metabolism can lead to severe toxicity or therapeutic failure by altering the relationship between dose and the blood concentration of the pharmacologically active drug. Although CYP2D6 has a wide range of genetic polymorphisms, they can be categorized into four groups: uttrarapid metabolizers containing multiple copies of the CYP2D6 gene, extensive metabolizers with a single wild-type copy of the CYP2D6 gene, intermediate metabolizers (heterozygotes) exhibiting decreased enzymatic activity, and poor metabolizers (homozygotes) with no detectable activity (5) . About 5-10% of Caucasians are so-called poor metabolizers (PM) , that is, completely lacking CYP2D6 activity because of inactivating mutations or deletions in both alleles of the CYP2D6 gene (location 22q13.1) (6) . In many cases, the prediction of CYP2D6 activity is used to expIain or to predict outtiers in drug studies. Because therapeutic efficacy and adverse events in treatment with many drugs depends on CYP2D6 activity, the genotyping of CYP2D6 may become a routine part of individually optimized drug therapy.
In forensic toxicology, pharmacogenomics may aid in the certification of drug toxicity. This is extremely important because pharmaceutical agents are one of the most commonly identified causes of adverse events, resulting in significant morbidity and mortality (7, 8) . Analgesics, such as oxycodone, are the primary substance in 30% of all reported fatalities according to the 2000 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System (9) . In fact, hospital emergency room reports of oxycodone-related incidents have nearly doubled since 1996 (10) .
Oxycodone (14-hydroxy-7,8-dihydrocodeinone), a semi-synthetic opioid agonist, is frequently prescribed for the relief of moderate to severe pain. Oxycodone is extensively metabolized in the liver to noroxycodone and oxymorphone. Noroxycodone is the major circulating active metabolite of oxycodone with an area-under-the-curve ratio of 0.6 relative to that of oxycodone. Oxymorphone, whose formation is mediated by CYP2D6, is present in lower plasma concentrations. Because oxycodone has a high bioavailability after oral administration and its analgesic properties are equivalent to morphine, the medical use of oxycodone has increased 23% as reported in the Journal of the American MedicalAssociation (11) . Several recent reports by the Drug Abuse Warning Network also show that oxycodone abuse has significantly risen as indicated by the increase in oxycodone mentions in Medical Examiner's reports. In fact, a controlled-release formulation of oxycodone, OxyContin | was believed to be responsible for more than 120 fatal overdoses among drug abusers in recent years in several states, including Maine, Kentucky, Virginia, Ohio, and Florida. In addition, the Drug Enforcement Administration has received 291 coroners' reports of oxycodone-related deaths from 6 states where OxyContin consumption was the highest (12) . In the United States, OxyContin is the leading narcotic analgesic sold in tablet form with sales of over $1 billion (13) .
Although the abuse of oxycodone may result in toxicity, poor drug metabolism because of CYP2D6 deficiency may also play a significant role. Therefore, postmortem drug concentrations of oxycodone should be interpreted in conjunction with the medical history, death scene investigation, autopsy findings, postmortem interval, and pharmacogenomics. In this preliminary study, the prevalence of CYP2D6 deficiency was examined in oxycodone-related deaths. We hypothesized that oxycodone fatalities due to drug toxicity could be attributed, in part, to the CYP2D6 variant alleles, which would result in the poor metabolism of oxycodone and other drugs. As a result, cases from the Milwaukee County Medical Examiner's Office that included oxycodone in the cause of death from January 2000 to March 2002 were examined. The prevalence of CYP2D6 was established using conventional and real-time PCRs and correlated with other pertinent case information to assess the usefulness of pharmacogenomics in certifying the cause and manner of death.
Methods

Case selection
The Institutional Review Board of the Medical College of 
Control group
To establish the prevalence of CYP *3, *4, and *5 in the general population, 26 volunteers were genotyped.
Autopsy
Because all the drug deaths were considered sudden, unexpected, or suspicious, a complete autopsy was performed at the Milwaukee County Medical Examiner's Office. A complete autopsy included dissection of the thoracic, abdominal, cranial, and neck compartments. When possible, specimens of subclavian blood and vitreous fluid were collected by the investigator during initial body examination at the scene, cremation views, or at the time of admission to the Medical Examiner's Office. During the autopsy, additional specimens were collected, including vitreous fluid and subclavian blood, if not previously done, bile, urine, peripheral blood (iliac) or in the absence of peripheral blood, aortic or heart blood, a portion of liver, representative gastric contents, pulled head hair, and a dried blood sample for DNA analysis. The blood specimens were preserved with 2% sodium fluoride. All specimens were stored at 4~ immediately following collection at autopsy.
Toxicological analysis
All cases were subject to a full toxicological examination. When drugs were present at the initial scene investigation or further case investigation and medical history indicated the use of therapeutic or abused drugs that would not otherwise be routinely detected and identified by the described analytical techniques, tests were conducted either on-site or sent to an outside toxicology reference laboratory to include these drugs as part of the comprehensive toxicological examination.
Comprehensive toxicological examination for each case included screening tests for alcohols and carboxyhemoglobin, as well as therapeutic and abused drugs by a combination of color tests, immunoassays, and chromatographic techniques including thin-layer (TLC), gas chromatography (GC) with flame ionization detector (PID), and gas chromatography-mass spectrometry (GC-MS). Acid-dichromate test was used for detection of methyl, ethyl, isopropyl alcohol, acetone, and acetaldehyde. Blood was analyzed on the IL 482 or 682 Co-oximeter for the presence of carboxyhemoglobin. Routine urine color spot tests were performed for detection of acetaminophen metabolites, ethchlorvynol, salicylates, and phenothiazines. Urine specimens were screened for the presence of acidic, neutral, and basic drugs by the Toxi-Ix~b TM AB TLC system by ANSYS (Irvine, CA). Urine EMIT TM immunoassay screens were performed for detection of amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine metabolite, and opiates. Therapeutic and abused drugs were extracted from blood using a 300-rag Clean Screen | solid-phase extraction column (United Chemical Technologies Inc., Bristol, PA) with subsequent detection by GC or GC-MS. (14) Immunalysis TM radioimmunoassay kits (Immunalysis Corp., San Dimas, CA) were used for the detection of amphetamines, benzodiazepines, cannabinoids, cocaine metabolite, and opiates in blood. Analytes detected by initial screening methodologies were then confirmed by an alternate analytical methodology and quantitated for assessment of drug toxicity. Blood chromatographic screening, confirmation, and quantitation techniques used established GC or GC-MS protocols. (15, 16) 
Initial urine drug screen
Toxi-Lab A, a TLC basic/neutral drug detection system, was used as the screening method for the initial detection and presumptive identification of oxycodone in urine specimens on cases submitted for a comprehensive toxicology analysis. The detection limit for oxycodone by this method is approximately 1.0 mg/L in 5 mL aqueous solution.
Oxycodone was extracted from urine using a liquid-liquid extraction technique for subsequent GC-MS confirmation. For the extraction procedure, 5 mL of urine specimen was pippetted into a 15-mL centrifuge tube followed by addition of the internal standard, promazine, at a concentration of 1.0 mg/L, then buffered to a basic pH with addition of potassium carbonate, vortex mixed for 10 s, and centrifuged. After centrifugation, the supernatant was transferred to a clean 5-mL centrifuge tube. While vortex mixing, 100 laL of extraction solvent, 5% isobutanol in chloroform, was added. The specimen was then centrifuged an additional 10 min, and an aliquot (~ 3 IJL) of the solvent extract was injected into the GC-MS for confirmation.
Initial blood drug screen
A solid-phase extraction (SPE) method for therapeutic and abused drugs (14) and GC-MS analysis was performed for extraction, detection, and identification of oxycodone in blood specimens submitted for screening. Promazine, at a concentration of 1.0 rag/L, was used as an internal standard and added to the blood specimen prior to extraction. The column used for extraction was a 300-mg Clean Screen copolymeric SPE column (United Chemical Technologies). The extract was then analyzed by GC-MS.
Initial blood screens and subsequent urine and blood confirmations were analyzed by full scan electron impact GC-MS. A Hewlett-Packard model 5890 GC equipped with a 5972 mass selective detector (MSD) was used for analysis. Chromatographic separation was achieved using either a DB-5 MS ( and 300~ respectively. Identification and confirmation of oxycodone was based on (1) retention time at 12 min and (2) mass spectral match with drug identification library, showing base peak ofm/z 315 with other prominent ion peaks atm/z 230, 70, 258, and 140. In cases in which oxycodone use was suspected based on the initial scene investigation or further investigation into the case and medical history, but not detected by routine screening methods, blood extracts were re-injected into the GC-MS using selective ion monitoring (SIM) mode for the prominent ions of oxycodone. This procedure resulted in increased assay sensitivity for the detection of oxycodone at 0.01-0.025 mg/L.
Final oxycodone quantitation
Oxycodone was quantitated by either GC-FID or GC-MS in SIM mode. For the GC-FID method, blood extracts were analyzed on a Hewlett-Packard model 5890 GC with splitless injection, dual columns, and dual flame ionization detectors. Chromatographic separation was achieved using DB-5 and DB-17 capillary columns (J&W Scientific, Folsom, CA) with the following dimensions: 15 m x 0.25-ram i.d. and 0.25-~m film thickness. Chromatographic conditions used are described here. Basic drugs detected by initial screening methods are quantitated simultaneously by this method with a limit of quantitation for oxycodone of 0.2 mg/L.
An SPE method for underivitized opiates (17) and GC-MS SIM mode analysis was performed for extraction, confirmation, and quantitation of oxycodone detected by initial SIM mode monitoring. Standards and controls were prepared by spiking drug-free blood with known amounts of oxycodone to concentrations ranging from 0.01 to 0.50 mg/L. Codeine-d3, at a concentration of 0.10 rag/L, was used as an internal standard and added to the blood specimens prior to extraction. The column used for extraction was a 300-mg Clean Screen copolymeric SPE column (United Chemical Technologies Inc.). A Hewlett-Packard model 5890 GC equipped with a 5972 MSD was used for analysis. Chromatographic separation was achieved using either a DB-5 MS (J&W Scientific) or HP-5 (Agilent Technologies, Palo Alto, CA) capillary column with the following dimensions: 15 m x 0.25-mm i.d. and 0.25-1Jm film thickness. The oven temperature was programmed to start at 100~ initial hold time of 1 rain, followed by a 15~ rise to a temperature of 300~ with a final hold time of 2 rain (total analysis time of 16 rain). Temperatures of the injector and detector were 250~ and 300~ respectively. The extract was then analyzed by GC-MS SIM mode monitoring for the following ion peaks: oxycodone at m/z 315, 230, and 258 and codeine-d3 (internal standard) at m/z 302, 165, and 202. Retention times for oxycodone and codeine-d3 are approximately 12 and 11.1 rain, respectively. Limit of detection for oxycodone is 0.01 mg/L with a limit of quantitation of 0.025 mg/L with this method.
DNA extraction
The DNA was extracted from the white blood cells using the PUREGENE | DNA isolation kit (Gentra Systems, Minneapolis, MN). Briefly, 3 mL of whole blood was added to a 15-mL tube containing 9 mL of red blood cell lysis solution, mixed, and incubated for 10 rain. The samples were then centrifuged at 2000 x g for 10 min and the supernatant was removed. Cell lysis solution (3 mL) was then added and vortex mixed to resuspend the cells. Rnase A solution (15 lJL) was added to the cell lysate and incubated at 37~ for 15 min. The samples were cooled on ice and 1 mL of protein precipitation solution was added to the cell lysate. The samples were vortex mixed and centrifuged at 2000 xg for 10 rain. The supematant containing the DNA was poured into a 15-mL tube, containing 3 mL 100% isopropanol, and mixed. The samples were then centrifuged at 2000 xg for 10 rain. The supernatant was removed and the DNA was washed with 3 mL of 70% ethanol and re-centrifuged at 2000 x g for 1 min. The DNA was then allowed to air dry (10-15 rain) and finally re-hydrated in DNA hydration solution (250 ~L). The DNA was then quantitated and checked for purity by spectrophotometric methods. After analysis, the samples were stored at-20~
Genotyping protocols
The amplification/detection of 21)6"4 by the LightCycler | required 100 ng of DNA sample. The PCR reaction contained 2001JM of each nucleotide (dUTP, dTTP, dATP, dCTP, and dGTP, Amersham Pharmacia Biotech, Piscataway, N J), lmM magnesium with bovine serum albumin (Mg § w/BSA, Idaho Technology, Salt Lake City, UT), 500 nM of each 21)6"4 primer as previously described (18) The amplification/detection for 2D6"3 by the LightCycler was similar with the following changes: 2.5raM of Mg § w/BSA, no buffer, a different set of hybridization probes (anchor probe: 5'-CGC TTC CAA AAG GCT TTC CTG ACC CAG CTG GAT GAG C-FITC-3'; mutant probe: 5'-LGC TAA CTG AGC ACA GGA TGA C-P-3' (L = Amino linker/LC Red705, P = Phosphate)), and 750nM of forward primer and llJM of reverse primer, was used as previously described (19) . CYP2D6*5 was amplified by conventional long PCR (20, 21) . The protocol was adapted from Hersberger et al. (20) with several key modifications. Briefly, after DNA extraction, amplification was performed with Amplitaq Gold and G46E enzyme (Roche Molecular Systems, Alameda, CA) that allowed the use of uracil-N-glycosylase and uracil for decontamination. Amplification was performed for 35 cycles, followed by analysis by 0.8% agarose gel with ethidium bromide staining. Wild-type showed a 5-kb band, homozygous showed a 3.2-kb band, and heterozygous showed two bands corresponding to 5 and 3.2 kb.
Statistical analysis
Fisher's Exact test and frequency tables were calculated with SAS statistical software (The SAS Institute, Cary, NC). Analysis of variance (ANOVA) was also calculated. Other drugs were also identified in every case except case 1. Other drugs identified in the 14 cases included, in order of prevalence: 7 diazepam, 4 diphenhydramine, 3 acetaminophen, 3 hydmcodone, 2 venlafaxine, 2 nortriptyline, and I each of cocaine, clonazepam, cyclobenzaprine, meperidine, methadone, amitriptyline, carisoprodol, meprobamate, citalopram, fentanyl, tramadol, and phenytoin. Alcohol was detected in four cases with concentrations from 80 to 260 mg/dL. Certifications listed the following causes of death: 11 mixed drug toxicity and 4 oxycodone overdose. The manners of death included 9 accidental, 3 suicide, and 3 undetermined. Table II shows the prevalence of the CYP2D6*3, *4, and *5 alleles in the 15 cases from the Medical Examiner's Office and compares them with the control group (n = 26) not prescribed oxycodone. The prevalence in the control group was as follows: one homozygous and three heterozygous for CYP2D6*4, one heterozygous for both CYP2D6*4 and *5, and one heterozygous for CYP2D6*5. The prevalence of poor metabolizers between groups was not statistically significant (p = > 0.05, Fisher's Exact Test). The prevalence of poor and intermediate metabolizers combined was also not significantly higher than the control group (p = > 0.05, Fisher's Exact Test).
Results
Between
For assessing the role of pharmacogenomics as an adjunct for death certification, cases 1-6 (representing the poor and intermediate metabolizers) were reviewed.
Case 1: A 49-year-old white male had a social history of drug use, a medical history of depression and post-traumatic stress disorder, and one past suicide attempt. The death scene investigation showed that only 12 of the 60 oxycodone pills remained from his prescription that was filled the previous day. The decedent was last seen alive by his roommate in the morning. After returning from work, the roommate discovered the decedent unresponsive in his bed.
Case 2: A 48-year-old white male, with a current history of prescription medication abuse and a past history of alcohol and cocaine abuse, had reportedly taken additional oxycodone for his continuous back pain. However, after going to the grocery store, the decedent was incapable of driving. As a result, the decedent returned home in a cab and went to bed. Later that day, the decedent was found not breathing.
Case 3: A 43-year-old white female had a medical history that included stomach stapling and several hernia surgeries. The decedent suffered from a low tolerance to pain. Six days prior, the decedent had undergone another hernia surgery without any complications. After returning home, the decedent was in a lot of pain and very drowsy. The next few days were unremarkable. On the sixth day after the hernia surgery, the decedent was found lifeless in her bed. Upon review of her medications, a deficit in her oxycodone pills was found. Case 4: A 48-year-old black female had a history of clinical depression and abuse of her prescription medications. Thus, a neighbor had been administering the majority of the medications to the decedent, except diazepam and oxycodone. There were no recent suicidal ideations. She was found dead in the living room of her apartment with an empty bottle of Valium in her hand.
Case 5: A 43-year-old male with a social history of alcohol and drug use was last seen at a party the previous night. After leaving the party, the decedent was found unresponsive on the lawn the following morning.
Case 6. A 39-year-old female was last seen by her boyfriend after they had a verbal argument. The boyfriend found her sitting up on the bed, slumped forward in their secure apartment. A syringe filled with blood was found on the nightstand beside her. A tourniquet was noted around her right ankle with two possible injection sites. In addition, a spoon was found with a white cooked substance. The white substance was taken into evidence by the police and tested and identified as oxycodone by the State Crime Laboratory.
Cases 7-15 with wild-type CYP2D6 showed multiple drug intoxications with the cause of death being attributed solely to oxycodone in case 14. Table III lists the genotype classifications along with other important covariabIes including opioid naive, chronic use of alcohol, use of prescription drugs or drugs of abuse, acute versus chronic ingestion, and the postmortem interval. Chronic pain patients who took additional doses above the prescribed dose were classified as acute on chronic. However, covariables were not correlated to a particular genotype classification. 
Discussion
Interindividual differences in the experience of pain and the response to analgesic pharmacotherapies have been clinically appreciated for over a century (22) . Although it was not until recently that pharmacogenomics, an emerging discipline that focuses on the genetic determinants of drug response, has been applied for individualized drug therapy (personalized medicine). Because concentration and effect of drugs are dependent on the genomics of the patient's drug metabolizing enzymes, transporters, and receptors, a rational drug regimen may be designed by determining a patient's genotype (23, 24) . The use of pharmacogenomics in the prevention of adverse drug reactions is extremely important because adverse drug reactions in 1994 ranked between the 4th and 6th leading causes of death in the United States (25) . Pharmacogenomics may also have the potential to become a supplemental tool for forensic toxicology (10) .
Oral opiates such as codeine and oxycodone are metabolized to morphine and oxymor- phone, respectively, which have increased pharmacological activity (26) . Oxycodone is metabolized by means of O-demethylation in the liver by the polymorphic enzyme CYP2D6. Although the majority of the populations are extensive metabolizers of CYP2D6, 5-10% of Caucasians and 1-4% of most other ethnic groups (2, 27) have decreased CYP2D6 activities with increased risk of toxic effects and possible fatality from routine clinical doses of oxycodone. Because CYP2D6 is highly polymorphic, the optimization of pain management therapy with oxycodone may be enhanced by genotyping patients. Patients with a CYP2D6 deficiency would require dose reduction or be placed on an alternative drug not metabolized by CYP2D6 (28) . This approach has also been recommended for antidepressant therapy in which the majority of the drugs used are metabolized by CYP2D6 (29) . Therefore, patients who are classified as poor metabolizers (homozygous) should be started on a lower dose of the medication. Currently, patients who are intermediate metabolizers (heterozygous) are classified as extensive metabolizers with reduced enzyme activity (29, 30) . These intermediate metabolizers are an important subset of the population (10-15% of caucasians) who have partially impaired but residual in vivo function (31) . Together, these poor and intermediate metabolizers are more likely to experience light-headedness, dizziness, sedation, nausea, and vomiting. Other adverse events include euphoria, constipation, skin rash, and pruritus. In addition, like all opioids, oxycodone can cause respiratory depression, apnea, respiratory arrest, circulatory depression, hypotension, and/or shock.
In general, peak plasma concentrations of oxycodone are achieved within 0.8-2.5 h post dose (32) . The average elimination half-life of oxycodone is 5.1 h (33). Fatal concentrations of oxycodone in adults following acute ingestion are between 0.4 and 0.7 mg/L (34). However, oxycodone concentrations greater than 0.1 mg/L in conjugation with elevated concentrations of antidepressants and/or certain other prescription drugs may also cause death (35) . The potential problem is that many clinical and forensic laboratories use immunoassays to screen samples. Immunoassays are not well suited for monitoring therapeutic use, compliance, or abuse of oxycodone because of the low antibody cross-reactivity in commercially available kits (36) . As a result, GC-MS or liquid chromatography-mass spectrometry analysis with SIM monitoring of prominent ions is recommended to detect therapeutic concentrations of oxycodone (36) .
In the certification of oxycodone toxicity, a complete toxicology/medical history, autopsy findings, and death scene investigation should be interpreted. In addition, the acute or chronic use of oxycodone, the opioid na'fve response, the possibility of accidental overmedication to relieve pain, and the accumulation of oxycodone as a consequence of reduced clearance must be considered. Other covariables that could affect the concentration of oxycodone include the sampling site and postmortem drug redistribution. Postmortem drug redistribution according to Fallani (37) , may be characterized by four periods: I, II, III, and IV, corresponding to the time periods of < 24, 24-48, 48-72, and > 72 h, respectively. Because peripheral blood is less subject to postmortem redistribution, it is the preferred sample to be used for analysis, especially in periods III and IV. Because oxycodone may exhibit postmortem redistribution, oxycodone bound to neighboring tissues may diffuse into the surrounding blood/fluid. In fact, a heart/femoral blood concentration ratio of 3:1 was observed for oxycodone in one case (38) .
In interpreting elevated concentrations of oxycodone, a large number of covariables must be considered. Tables I and III list the various cases with their corresponding genotype results and other relevant covariables. In general, most of the decedents were not opioid naive and were prescribed oxycodone for their chronic pain. In addition, alcohol and alcoholism were not prevalent covariables in these cases. Furthermore, the majority of these cases involved acute or acute on chronic ingestions of oxycodone. Cases 1-6 are further reviewed in regards to their genotype and selected covariables that may aid in the interpretation of the oxycodone toxicity.
In case 1, oxycodone was the only drug detected. The autopsy showed hepatic cirrhosis and atherosclerotic heart disease. The decedent had a medical history of chronic lower back pain and surgery and was prescribed both OxyContin and Percocet TM. As a result, the decedent was not opioid naive. In addition, the decedent was an alcoholic. Because the postmortem interval was < 24 h and subclavian blood was used, the elevated concentration of oxycodone was not due to postmortem redistribution. So in the absence of any recent suicide ideation, the poor metabolizer phenotype conferred by CYP2D6 deficiency and impaired metabolism because of hepatic cirrhosis, may have contributed to the fatal oxycodone concentration. The decedent in case 2 had a history of prescription drug abuse. The CYP2D6 genotype (poor metabolizer) along with the additional doses of OxyContin taken may have contributed to the elevated concentration of oxycodone. For case 3, the decedent suffered from a recent hernia surgery and a low tolerance to pain. As a result, the decedent had been prescribed both OxyContin (a controlled-release formulation of oxycodone) and Roxiceff M (which contains acetaminophen and oxycodone). In addition, the decedent had taken other depressant drugs (Table I) . One of the other drugs detected, meperidine, is also a substrate for CYP2D6 and could possibly interact with oxycodone resulting in an elevated concentration. On the other hand, postmortem redistribution did not contribute to the increased oxycodone concentration because iliac blood was used and the postmortem interval was < 24 h. The autopsy findings revealed the presence of nine oxycodone tablets in the stomach. In the absence of any direct evidence to suggest a deliberate overdose of oxycodone, the fatal concentrations of oxycodone may have been due to accidental overmedication to relieve pain. Nevertheless, the decreased metabolic phenotype (heterozygous) may have also contributed to the elevated concentration of oxycodone. In case 4, the decedent had a history of suicide and prescription medication abuse. Numerous drugs were found including oxycodone, diazepam, acetaminophen, venlafaxine, diphenhydramine, and cyclobenzaprine. Venlafaxine is both a substrate and a weak inhibitor of CYP2D6 (39) . Because of the elevated concentrations of oxycodone, cyclobenzaprine, and diphenhydramine and the acute ingestion of venlafaxine, the cause of death was identified as mixed drug toxicity. Since the manner of death was suicide, the intermediate metabolizer phenotyped did not contribute to certification in cause of death. The decedent in case 5 had a history of alcohol and drug abuse. The high oxycodone concentration may have been due to a combination of acute ingestion of oxycodone and/or impaired metabolism due to CYP2D6 *4 deficiency and CYP2D6 inhibition by methadone. Together, the alcohol, methadone, and oxycodone resulted in his sedation and the cause of death was mixed drug overdose. For case 6, oxycodone was detected in the syringe used by the decedent. Therefore, the decedent had acutely injected a lethal amount of oxycodone (subclavian blood concentration 2 rag/L). In this case, the heterozygous genotype did not play a significant role because the excessive oxycodone was self-administered. In cases 7-15, the genotype did not play a role in the death as all were wild-type (extensive metabolizers) for CYP2D6.
A recent study examined the use of CYP2D6 genotyping on § ~ ovarlables considered~'~ postmortem blood as a supplementary tool for the interpretation of forensic toxicology results for cases with high metabolic ratios (10) . This study concluded that the poor metabolizer phenotype was not very frequent, and that drug-drug interactions in extensive metabolizers constituted a more frequent and important finding (10) . Because the population size was small and there was a Iack of poor metabolizers, the frequencies of these polymorphisms may not accurately represent those in the general population. Despite the limited size of our study, our findings revealed the presence of extensive, intermediate, and poor metabolizers in both populations. As a result, a proposed algorithm for the use of pharmacogenomics in forensic toxicology is presented in Figure 1 . Our model also takes into account various covariables such as acute or chronic toxicity, autopsy findings, site of sample collection, postmortem interval, concomitant drug use, case/medical history, death scene investigation, and intent. Currently, this algorithm is being used as a guideline for selected forensic toxicology cases at the Milwaukee County Medical Examiner's Office. Initially, the Medical Examiner, forensic pathologists, and personnel from the toxicology laboratory meet to review the cases. Based on the autopsy findings, case his-,, tory, and death scene investigation, a compre-0---] hensive or more specific drug screen may be performed. If an elevated drug concentration is found, the case and toxicology findings are reassessed. Several important covariables are examined to help interpret the elevated drug concentration. One of the covariables considered is the intent of the decedent. The death certification can be finalized if the decedent was suicidal. In addition, the sample site of the specimen that revealed the elevated drug concentration and the Fallani interval were examined because postmortem redistribution may cause elevated drug concentrations. The presence of other drugs at the time of death is also considered, as drug-drug interactions may contribute to the elevated drug concentration. Finally, the issue of pharmacogenetics was examined to determine if there is a genetic explanation for the elevated drug concentration. In other words, does a polymorphic enzyme metabolize the drug that was detected at concentrations that exceeded the normal therapeutic range? In several cases with elevated drug concentrations, pharmacogenomics has provided a more definitive interpretation of the toxicity.
Overall, CYP2D6 genotyping served as a useful adjunct in the certification of oxycodone toxicity, particularly in cases 1, 2, 3, and 5. However, the prevalence of CYP2D6 variant alleles between the Medical Examiner and control groups was not statistically significant because of the small sample size. Therefore, the appropriateness of using CYP2D6 genotyping in oxycodone toxicity cases awaits a further study with a larger sample size. A power analysis indicates that for a 10% prevalence of a particular polymorphism in a population, a minimum sample size of 370 subjects would be needed. Statistical significance may be evaluated for the wild-type in comparison with those with variant alleles. In addition, the control group should ideally be a group of patients being treated with oxycodone. Despite these limitations, this study did show that genotyping CYP2D6 can be used as molecular autopsy for forensic toxicology.
Conclusions
Genotyping of CYP2D6 *3, *4, and *5 may serve as a molecular autopsy for certifying oxycodone mortality. This preliminary study showed a higher prevalence of poor and intermediate metabolizers in the oxycodone-related deaths at the Medical Examiner's office compared with the control group. Even though the findings were not statistically significant, the genotyping provided additional useful information in determining the cause/manner of death. Future studies with a larger sample size are needed to prove statistical significance. Because the number of oxycodone cases in some medical examiner's office may be limited, a multi-center collaboration between medical examiners offices may be required. Nevertheless, the application of pharmacogenomics in forensic toxicology may provide a rational basis for the understanding of various drug-related fatalities.
